Who is first in line? Trends in use of poly (ADP-ribose) polymerase inhibitors (PARPi) among commercially insured women with ovarian cancer

Joseph Dottino,Stephanie Argetsinger,Rebecca Costa,Katharine Esselen,Dennis Ross-Degnan,Anita Wagner

GYNECOLOGIC ONCOLOGY（2023）

引用 0|浏览7

暂无评分

摘要

The first PARPi was approved for use in ovarian cancer (OC) in 2014. Later approvals and expanding indications have made more patients eligible for PARPi therapy. This study assessed population-level trends in PARPi use over time.

查看译文

关键词

polymerase inhibitors,ovarian cancer,parpi,adp-ribose

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要